Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» eptinezumab
eptinezumab
The fourth CGRP migraine drug is here. Time for Lundbeck to prove it's worth $2B
Endpoints
Sat, 02/22/20 - 11:29 pm
Lundbeck
eptinezumab
migraines
CGRPs
Vyepti
Faint hope for Alder as Teva bucks dismal migraine trend
EP Vantage
Thu, 05/2/19 - 11:12 am
migraines
Alder Biopharmaceuticals
Teva
Eli Lilly
Amgen
Emgality
Ajovy
eptinezumab
FDA accepts BLA for Alder's migraine therapy for infusion
BioCentury
Mon, 04/22/19 - 06:59 pm
Alder Biopharma
FDA
eptinezumab
migraines
Why Alder thinks its late-comer migraine drug can succeed
Biopharma Dive
Thu, 04/11/19 - 12:28 pm
Alder Biopharmaceuticals
migraines
eptinezumab
New Data For Alder BioPharmaceuticals' Eptinezumab Shows Long-Term Reduction in Episodic Migraine
CP Wire
Wed, 04/25/18 - 11:06 am
Alder BioPharmaceutical
eptinezumab
migraines
New Data For Alder BioPharmaceuticals' Eptinezumab Shows Long-Term Reduction in Episodic Migraine
Tue, 04/24/18 - 11:52 pm
Alder BioPharmaceutical
eptinezumab
migraine
Teva, Alder ink migraine deal to avoid legal headache
Biopharma Dive
Tue, 01/9/18 - 10:53 pm
Teva Pharmaceutical
Alder Biopharmaceuticals
migraines
eptinezumab
Alder prices $150M offering to fund migraine market scrap
Fierce Biotech
Thu, 07/13/17 - 05:33 pm
Alder Biopharma
migraines
eptinezumab
Little Alder bags positive PhIII migraine data, but giant rivals are racing ahead in a crowded field
Endpoints
Tue, 06/27/17 - 09:38 am
Alder Biopharma
migraines
clinical trials
eptinezumab
Eli Lilly
Amgen
Novartis
Merck